1 University of Tennessee College of Pharmacy, Memphis.
2 University of Texas MD Anderson Cancer Center, Houston.
J Manag Care Spec Pharm. 2018 Feb;24(2):97-107. doi: 10.18553/jmcp.2018.24.2.97.
Previous research found racial and ethnic disparities in meeting medication therapy management (MTM) eligibility criteria implemented by the Centers for Medicare & Medicaid Services (CMS) in accordance with the Medicare Modernization Act (MMA).
To examine whether alternative MTM eligibility criteria based on the CMS Part D star ratings quality evaluation system can reduce racial and ethnic disparities.
This study analyzed the Beneficiary Summary File and claims files for Medicare beneficiaries linked to the Area Health Resource File. Three million Medicare beneficiaries with continuous Parts A, B, and D enrollment in 2012-2013 were included. Proposed star ratings criteria included 9 existing medication safety and adherence measures developed mostly by the Pharmacy Quality Alliance. Logistic regression and the Blinder-Oaxaca approach were used to test disparities in meeting MMA and star ratings eligibility criteria across racial and ethnic groups. Multinomial logistic regression was used to examine whether there was a disparity reduction by comparing individuals who were MTM-eligible under MMA but not under star ratings criteria and those who were MTM-eligible under star ratings criteria but not under the MMA. Concerning MMA-based MTM criteria, main and sensitivity analyses were performed to represent the entire range of the MMA eligibility thresholds reported by plans in 2009, 2013, and proposed by CMS in 2015. Regarding star ratings criteria, meeting any 1 of the 9 measures was examined as the main analysis, and various measure combinations were examined as the sensitivity analyses.
In the main analysis, adjusted odds ratios for non-Hispanic blacks (backs) and Hispanics to non-Hispanic whites (whites) were 1.394 (95% CI = 1.375-1.414) and 1.197 (95% CI = 1.176-1.218), respectively, under star ratings. Blacks were 39.4% and Hispanics were 19.7% more likely to be MTM-eligible than whites. Blacks and Hispanics were less likely to be MTM-eligible than whites in some sensitivity analyses. Disparities were not completely explained by differences in patient characteristics based on the Blinder-Oaxaca approach. The multinomial logistic regression of each main analysis found significant adjusted relative risk ratios (RRR) between whites and blacks for 2009 (RRR = 0.459, 95% CI = 0.438-0.481); 2013 (RRR = 0.449, 95% CI = 0.434-0.465); and 2015 (RRR = 0.436, 95% CI = 0.425-0.446) and between whites and Hispanics for 2009 (RRR = 0.559, 95% CI = 0.528-0.593); 2013 (RRR = 0.544, 95% CI = 0.521-0.569); and 2015 (RRR = 0.503, 95% CI = 0.488-0.518). These findings indicate a significant reduction in racial and ethnic disparities when using star ratings eligibility criteria; for example, black-white disparities in the likelihood of meeting MTM eligibility criteria were reduced by 55.1% based on star ratings compared with MMA in 2013. Similar patterns were found in most sensitivity and disease-specific analyses.
This study found that minorities were more likely than whites to be MTM-eligible under the star ratings criteria. In addition, MTM eligibility criteria based on star ratings would reduce racial and ethnic disparities associated with MMA in the general Medicare population and those with specific chronic conditions.
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under award number R01AG049696. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Cushman reports an Eli Lilly grant and uncompensated consulting for Takeda Pharmaceuticals outside this work. The other authors have no potential conflicts of interest to report. Study concept and design were contributed by Wang and Shih, along with Wan, Kuhle, Spivey, and Cushman. Wang, Qiao, and Wan took the lead in data collection, with assistance from the other authors. Data interpretation was performed by Wang, Kuhle, and Qiao, with assistance from the other authors. The manuscript was written by Spivey and Qiao, along with the other authors, and revised by Cushman, Dagogo-Jack, and Chisholm-Burns, along with the other authors.
先前的研究发现,根据医疗保险和医疗补助服务中心(CMS)按照《医疗保险现代化法案》(MMA)实施的药物治疗管理(MTM)资格标准,存在种族和民族差异。
研究替代 MTM 资格标准,该标准基于 CMS 部分 D 星级评级质量评估系统,是否可以减少种族和民族差异。
本研究分析了医疗保险受益人的受益人摘要文件和索赔文件,并与地区卫生资源文件相关联。2012-2013 年,300 万名连续参加部分 A、B 和 D 的 Medicare 受益人参选。拟议的星级评级标准包括由药剂质量联盟主要制定的 9 项现有药物安全和依从性措施。使用逻辑回归和 Blinder-Oaxaca 方法检验了在种族和民族群体中,符合 MMA 和星级评级资格标准的差异。使用多项逻辑回归检验了通过比较符合 MMA 但不符合星级评级标准的个体和符合星级评级标准但不符合 MMA 的个体,是否存在差异减少。关于基于 MMA 的 MTM 标准,进行了主要和敏感性分析,以代表计划在 2009 年、2013 年报告的 MMA 资格标准的整个范围和 CMS 在 2015 年提出的标准。关于星级评级标准,将符合任何 1 项 9 项措施作为主要分析进行检验,并作为敏感性分析检验了各种措施组合。
在主要分析中,非西班牙裔黑人(backs)和西班牙裔人与非西班牙裔白人(whites)的调整后的优势比分别为 1.394(95%置信区间为 1.375-1.414)和 1.197(95%置信区间为 1.176-1.218)。在星级评级下,黑人比白人更有可能被认定为 MTM 合格,比例分别为 39.4%和 19.7%。在一些敏感性分析中,黑人比白人,西班牙裔人比白人更不可能被认定为 MTM 合格。根据 Blinder-Oaxaca 方法,差异不能完全用患者特征的差异来解释。每个主要分析的多项逻辑回归都发现了白人与黑人之间的调整相对风险比(RRR)存在显著差异,2009 年为 0.459(95%置信区间为 0.438-0.481);2013 年为 0.449(95%置信区间为 0.434-0.465);2015 年为 0.436(95%置信区间为 0.425-0.446);2009 年为 0.559(95%置信区间为 0.528-0.593);2013 年为 0.544(95%置信区间为 0.521-0.569);2015 年为 0.503(95%置信区间为 0.488-0.518)。这些发现表明,使用星级评级资格标准可以显著减少种族和民族差异;例如,与 2013 年的 MMA 相比,基于星级评级的黑人与白人符合 MTM 资格标准的可能性差异减少了 55.1%。在大多数敏感性和疾病特异性分析中也发现了类似的模式。
本研究发现,少数民族比白人更有可能符合星级评级标准下的 MTM 资格。此外,基于星级评级的 MTM 资格标准将减少与 MMA 相关的一般 Medicare 人群和特定慢性病患者的种族和民族差异。
本研究得到美国国立卫生研究院国家老龄化研究所的资助,资助号为 R01AG049696。本研究的内容仅由作者负责,不一定代表美国国立卫生研究院的官方观点。Cushman 报告说他有 Lilly 公司的资助,并且没有参与 Takeda Pharmaceuticals 的薪酬咨询。其他作者没有潜在的利益冲突需要披露。Wang 和 Shih 提出了研究的概念和设计,Wan、Kuhle、Spivey 和 Cushman 参与了研究。Wang、Qiao 和 Wan 带头进行了数据收集,其他作者也提供了协助。Wang、Kuhle 和 Qiao 对数据进行了解释,其他作者也提供了协助。Spivey 和 Qiao 撰写了手稿,其他作者也参与了修改,Cushman、Dagogo-Jack 和 Chisholm-Burns 对草稿进行了修订,其他作者也参与了修改。